Necroptosis is a programmed form of cell death triggered by death receptor ligands and stimuli able to induce expres-sion of death receptor ligands. In particular conditions, programmed cell death resembles necrosis and relies on a unique molecular pathway primed under apoptotic defi-cient conditions. The hub of the necroptosis pathway is the receptor-interacting protein kinase 1 (RIPK1), which recruits RIPK3 and mixed lineage kinase domain-like protein (MLKL) to form a regulatory necrosome complex. In vitro and in vivo studies provide evidence that RIPK1 and its partners are critical pathogenic determinants and markers of progres-sion and severity in several different inflammatory disorders, including neurodegenerative diseases, such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer???s disease, Parkinson???s disease, multiple sclerosis and Hunting-ton???s disease. A growing body of evidence pinpoints RIPK1 and the necrosome as novel potential therapeutic targets able to inhibit multiple cell death pathways and amelio-rate neuroinflammation alone or in combination with other treatments.

Targets to watch in neuroinflammation: focus on RIPK1

Romano, M
2022-01-01

Abstract

Necroptosis is a programmed form of cell death triggered by death receptor ligands and stimuli able to induce expres-sion of death receptor ligands. In particular conditions, programmed cell death resembles necrosis and relies on a unique molecular pathway primed under apoptotic defi-cient conditions. The hub of the necroptosis pathway is the receptor-interacting protein kinase 1 (RIPK1), which recruits RIPK3 and mixed lineage kinase domain-like protein (MLKL) to form a regulatory necrosome complex. In vitro and in vivo studies provide evidence that RIPK1 and its partners are critical pathogenic determinants and markers of progres-sion and severity in several different inflammatory disorders, including neurodegenerative diseases, such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer???s disease, Parkinson???s disease, multiple sclerosis and Hunting-ton???s disease. A growing body of evidence pinpoints RIPK1 and the necrosome as novel potential therapeutic targets able to inhibit multiple cell death pathways and amelio-rate neuroinflammation alone or in combination with other treatments.
Pubblicato
https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3391879&p_IsPs=N
File in questo prodotto:
File Dimensione Formato  
Targets to watch in neuroinflammation focus on RIPK1.pdf

Accesso chiuso

Descrizione: Articolo
Tipologia: Documento in Versione Editoriale
Licenza: Non specificato
Dimensione 2.47 MB
Formato Adobe PDF
2.47 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3027753
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact